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Abstract
Rheumatoid arthritis (RA) is a common destructive inflammatory
disease that affects 0.5–1% of the population in many countries.
Even though several new treatments have been introduced for
patients with RA, a considerable proportion of patients do not
benefit from these, and the need for alternative treatment strategies
is clear. This review explores the potential for a therapy targeting
the adaptive immune system by modulating co-stimulation of
T cells with a CTLA4–Ig fusion protein (abatacept).
Introduction
A large body of evidence has accumulated during recent
years describing the benefit of early control of inflammation in
order to avoid long-term disability and to maintain good
function in patients with rheumatoid arthritis (RA) [1–3]. The
introduction of tumour necrosis factor (TNF)-blocking agents,
in particular when they are given together with methotrexate,
has further improved the situation in terms of disease activity,
joint destruction and function for many patients [4–6]. This
success of therapies targeting TNF using monoclonal
antibodies or recombinant receptor constructs has set the
scene for the introduction of additional ‘biological’ therapies
that target key structures of the immune system. This has also
introduced a need to elucidate the roles played by various
immune events in the pathogenesis of RA in different groups
of patients with this disease, especially those who do not
benefit from TNF-blocking agents.
Blocking innate immune responses
Innate immune responses are rapid ways in which the
organism may eradicate pathogens. Cells that participate
include neutrophils, macrophages and natural killer cells.
Common for these cells is the ability to secrete inflammatory
mediators upon activation by rather unspecific stimuli from
microbial and other agents. In conditions such as RA, which
are characterized by chronic inflammation, these cells
contribute substantially to the (immune) pathology. Indeed,
during the 1990s blocking the proinflammatory cytokine TNF
was demonstrated to be beneficial in experimental arthritis [7]
and later also for human disease (see above). Furthermore,
blockade of IL-1, IL-6 and IL-15 has been tested in both
experimental arthritis in rodents [8,9] and in human RA
[10–12], with promising results.
Taken together, these data have led to a general belief that
innate immune responses are crucial to the manifestations of
RA, and that adaptive immune responses may be less
important in the pathogenesis of the disease and more
difficult to target. However, that belief over-simplifies this
complex disorder, and there are old as well as recent
indications that the adaptive immune system is also of major
pathophysiological importance in RA, and it may also be an
efficient target for RA therapy [13,14].
Blocking adaptive immune responses
Following the rapid immune reactions by cells of the innate
immune system, adaptive immune responses are mounted as
part of the normal immune response to pathogens. These
responses are characterized by their high specificity for the
antigen, and under normal conditions they are sequentially
upregulated and downregulated. Cells characteristic of the
adaptive immune system are B cells, T cells and professional
antigen-presenting cells (APCs; i.e. dendritic cells, macro-
phages and B cells).
B cells
B cells perform important functions as antibody-secreting
cells but they can also function as APCs and cytokine
producers. In RA, a role for B cells in the pathogenesis of the
disease has long been discussed [15–17]. First, rheumatoid
factor (i.e. anti-IgG Fc antibodies) is frequently present in sera
of patients with RA [18,19] and has even been used as a
prognostic marker for the development of an erosive disease
course [20]. Second, anti-citrullin antibodies are frequently
detected in RA patients [21–23]. These antibodies are very
specific for RA; they can appear before the onset of disease
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and so can be used as a prognostic marker for disease
development [24,25]. Both of these RA-associated antibody
responses are initiated with the help of activated T cells.
New therapies for RA are emerging that focus on the
adaptive arm of the immune system, one of them being
rituximab. Rituximab targets the CD20 molecule, which is
selectively expressed on B cells and depletes these cells
[26]. This treatment approach has yielded good responses in
the majority of rheumatoid factor positive RA patients treated
thus far, but more clinical research is necessary before it can
be widely applied clinically [17].
CD4+ T cells
T cells can be divided into CD4+ and CD8+ T cells; the former
are the classic helper cells and are crucial, for example, for
antibody production and activation of cytotoxic immune
responses. The CD4+ cells are also the dominant T cells in
inflammatory infiltrates in the synovia of RA patients [27,28].
The impact of this is further substantiated by the fact that
MHC class II is also abundantly expressed in the rheumatoid
synovium [28]; thus, T cells have the potential to become
reactivated locally in the joint. The importance of T cells in
arthritis was further validated in mice, in which disease can be
transferred to a naïve host by injecting T cells from an affected
animal [29]. Also, experimental disease can be controlled by T
cell depletion before initiation [30]. Thus, therapeutic
interventions targeting T cells have for some time remained an
attractive option in RA. However, further studies along this line
have been disappointing; in a first trial [31] targeting of CD4+
T cells with monoclonal antibodies did not affect disease
development. A different monoclonal antibody caused more
profound depletion of T cells [32], but this therapeutic
approach was associated with significant adverse effects and
mortality. In addition, using other available agents that interfere
specifically with T cell functions, such as cyclosporin, has
been only moderately successful [33], suggesting that we
must find more efficient agents that interfere with T cell
activation and investigate their benefit in clinical settings.
CD4+ T cells and co-stimulation
Both naïve and activated/memory T cells traffic in the
circulation. However, at the site of inflammation (e.g. the
rheumatic joint) only activated/memory T cells are found. This
is because of restriction of surface molecules that are needed
for homing to tissue, and these are not expressed on naïve
T cells [34]. A naïve T cell becomes activated after it
encounters antigen. The antigen is presented on HLA
molecules of APCs, but just recognition of antigen and MHC
by the T cell receptor is not sufficient for a naïve T cell to
become activated (Fig. 1a). Co-stimulation is also needed;
this is an interaction that sustains APC–T cell contact and
amplifies signals in the T cell [35]. The best characterized co-
stimulatory signal is that provided by CD28 expressed on
T cells ligating to CD80/86 (B7-1 and B7-2 molecules) on
APCs (Fig. 1b). CD28 ligation of naïve T cells has been
proven to be essential for IL-2 production and cell
proliferation [36]. Also, most activated/memory T cells retain
their surface expression of CD28, suggesting that this
molecule is also involved in reactivating T cells [37].
Since the initial description of CD28 and CD80/86, the list of
co-stimulatory molecules has steadily grown and includes
ICOS, CD134 (Ox40) and CD27, among others [38]. They
do not utilize the CD80 and CD86 molecules, and so the use
of a soluble blocking cytotoxic T lymphocyte-associated
antigen (CTLA)4–immunoglobulin (Ig) complex only prevents
‘classic’ co-stimulation mediated by CD28.
CTLA4 (CD152) is a molecule that can out-compete CD28
for ligation of the B7 molecules (Fig. 2). Its affinity for the B7
molecules is 10–20 times greater than that of CD28.
Biologically, these differences in affinity result in limitation and
subsequent downregulation in T cell responses. That this
mechanism is needed is clearly demonstrated in CTLA4
knockout mice, which die within 4 weeks of birth from
lymphoproliferative disease [39,40].
CTLA4–Ig fusion protein
The use a of CTLA4 fusion protein as a means to block B7
molecules has been well documented in experimental auto-
immunity [41–43]. Administration of CTLA4–Ig at the time of
immunization prevented collagen-induced arthritis. Interest-
ingly, administration after disease onset also ameliorated
disease [44]. Similar effects were obtained when a
combination of anti-CD80 and anti-CD86 antibodies were
used to block the co-stimulation, indicating the need to block
both pathways in the APC. Studies conducted by Tellander
Figure 1
Activation of naïve T cells requires (a) T cell receptor
(TCR)–peptide–MHC interaction (signal 1) and (b) co-stimulation
(signal 2) for full activation. This can be provided by so-called
professional antigen-presenting cells (APCs; i.e. dendritic cells,
macrophages and B cells). In the absence of co-stimulation the T cells
will become anergic. S17
and coworkers [45] indicate that antibody titres are also
decreased when CD80/CD86 are blocked, indicating the
importance of this co-stimulation pathway in B cell help.
These and several other experimental studies have led to the
development of the drug abatacept – a recombinant fusion
protein comprising the extracellular domain of human CTLA4
fused with a fragment of the Fc portion of human IgG1
(Fig. 3). A first study was conducted in patients with psoriasis
[46], among whom 46% achieved a 50% or greater
sustained improvement in clinical disease activity. More
recently, abatacept has also been administered to patients
with RA, with beneficial effects [47,48] (see also the article
by Ruderman and Pope in this supplement).
Levels of co-stimulation molecules in
rheumatoid arthritis
In addressing the potential mechanism of action of abatacept
in RA patients, it is of interest to examine whether levels of
CD28, CTLA4 and CD80/86 vary among cells in the
circulation and in different inflammatory compartments. A
comparison of CD28 levels on the surface of peripheral
blood cells of healthy individuals and RA patients [49] clearly
demonstrated the highest levels of CD28 in patients with
active disease. Also, CD28 expression is augmented in
T cells of the synovial tissue as compared with cells from
peripheral blood. This indicates that T cells in patients with
active disease have strong potential to interact with and
activate APCs, which in turn upregulate their CD80 and
CD86 expression and activate more T cells. It is well known
that the levels of CD80 and CD86 vary with the degree of
activation of the APC.
Analysis of CTLA4 levels in peripheral blood [49] indicated a
higher baseline level in RA patients than in healthy control
individuals. Upon in vitro activation the cell surface levels of
CTLA4 were similar in the two groups. Among RA patients
more cells with surface expression of CTLA4 were found in
synovial fluid than in peripheral blood [50].
Patients with co-stimulation deficient T cell
populations
There is one subgroup of patients in which CTLA4–Ig and B7
blockade can be assumed to be inefficient, and this is the
group with an expanded T cell population consisting of
CD28null cells [51]. These cells, lacking CD28 on their cell
surface, do not rely on co-stimulation for reactivation [52], and
as potent producers of proinflammatory cytokines they may be
at an advantage if the rest of the T cell pool, expressing CD28,
is suppressed by abatacept. Because these patients are easily
identified by flow cytometry, there are two principal options.
They can simply be excluded from treatment with abatacept
and receive alternative therapy instead, or they may be
identified in retrospect in order to investigate whether the
heterogeneity in response to CTLA4–Ig among RA patients
can be explained by the presence of this unusual cell
population. Heterogeneities in treatment response have also
been observed for most other antirheumatic drugs including
methotrexate and TNF-blocking agents. In all of these cases,
there is a need to identify those patients in whom each drug
has optimal efficacy and fewest adverse events.
Possible effects of CTLA4–Ig on protective
immune responses
Abatacept selectively modulates T cell activation through
blocking ‘classic’ co-stimulation. This selective action allows
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Figure 2
CD28 is constitutively expressed on T cells and CD86 is expressed on
antigen-presenting cells (APCs). (a) Upon activation CD80 is also
expressed on the APC and CD86 is further upregulated. (b) Cytotoxic
T lymphocyte-associated antigen (CTLA)4 expression is induced later
during activation, and out-competes CD28 for the interactions, thereby
inducing a downregulation in immune response.
Figure 3
CTLA4–Ig (cytotoxic T lymphocyte-associated antigen
4–immunoglobulin fusion protein) blocks the T cell–antigen presenting
cell (APC) interaction by binding to both CD80 and CD86, thus
preventing CD28 interaction. CTLA4 has a higher affinity for the B7
molecules than does CD28. TCR, T cell receptor.S18
other immune pathways to remain largely intact and ensures
that T cell activation is modulated rather than completely
blocked. The latter scenario would lead to immune
suppression and the potential for opportunistic infections.
This issue was addressed in the clinical psoriasis study [46],
in which immune responses against novel antigens also
occurred after initiation of treatment. This selective blockade
of CD28-dependent activation pathways was also observed
in experimental animal studies [53]; CD28 deficient mice
exhibited normal immune function in models of infection both
before and after treatment with CTLA4–Ig.
Consequences at the cellular level
How does CTLA4–Ig work from a cellular point of view? One
needs to remember that it does not target T cells directly.
Rather, it blocks APCs so that they cannot co-stimulate
T cells. Such blockade has direct functional consequences at
the APC level; for example, after co-culturing synovial cells in
the presence of CTLA4–Ig or anti-B7 antibodies, the amount
of proinflammatory cytokines produced by APCs was
reduced [54].
Other signalling pathways in the APC are also affected. It was
recently suggested that ligation of CTLA4–Ig with CD80/86
on the APC leads to activation of the enzyme IDO
(indoleamine-2,3-oxygenase); this enzyme has the potential to
modulate the function of the APC similar to that which has
been proposed to occur after interaction of APCs with
regulatory CD25+CD4+ T cells [55,56]. Thus, we speculate
that one mechanism of action of CTLA4–Ig is that it mimics a
function that naturally arising regulatory T cells have on APCs.
Over recent years evidence has accumulated that regulatory T
cells and the pathways that activate them may be of
significance for the development of RA. One such indication is
the fact that regulatory T cells are enriched at the site of
inflammation in the rheumatic joint, and that these T cells are
also functional in vitro and so they probably contribute to
regulation of local inflammatory reactions [57,58].
A functional consequence of blocking classic CD28-mediated
co-stimulation with abatacept is that it also leads to inhibition
of the proliferation of both circulating naïve and memory T
cells [59]. This may assist in reducing the number of activated
autoreactive T-cells available for entry into the synovium.
Interestingly, abatacept appears to have a ‘physiological
cousin’ in mice, in which a splice variant of CTLA4 is
expressed that is unable to bind the B7 molecules but
nevertheless gives a negative signal to T cells by co-localizing
with the T cell receptor and preventing T cell activation [60].
This is an interesting mechanism that adds to the various
other means by which peripheral tolerance may decrease the
chances of bystander activation of T cells. Only under optimal
circumstances, which include co-stimulation, will T cell
responses be elicited. Thus far, this phenomemon has not
been reported in humans.
Conclusion
T cells are key players in autoimmune diseases such as RA.
Once activated, they orchestrate potentially destructive
immune responses from other immune cells. Thus, by
preventing the initial activation and possibly reactivation of
T cells by abatacept, downstream damage mediated by
macrophages, fibroblasts and B cells may be controlled
(Fig. 4).
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